With gene therapy rapidly shifting from orphan to prevalent indications, the demand for viral vectors is surging—especially for adeno-associated virus (AAV). Yet the industry is still primarily operating on the legacy process of transient transfection, which requires large amounts of expensive GMP-grade DNA while carrying only limited scale-up potential. Nobody would consider such a process for industrial antibody production, but it is still the norm for AAV. The ELEVECTA™ platform of inducible stable AAV producer cell lines solves this issue.
In this webinar, we will dive deeply into the ELEVECTA™ technology to better understand how you can produce high-titer and high-quality AAV vectors as easily as antibodies.
